Genetic Disruption of 2-Arachidonoylglycerol Synthesis Reveals a Key Role for Endocannabinoid Signaling in Anxiety Modulation

Cell Reports

Volumn 9, Issue 5, 2014, Pages 1644-1653

  Shonesy, Brian C ^a   Bluett, Rebecca J ^a   Ramikie, Teniel S ^a   Báldi, Rita ^a   Hermanson, Daniel J ^a   Kingsley, Philip J ^a   Marnett, Lawrence J ^a   Winder, Danny G ^a,b   Colbran, Roger J ^a,b   Patel, Sachin ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ARACHIDONIC ACID; DIACYLGLYCEROL LIPASE ALPHA; ENDOCANNABINOID; ESTERASE INHIBITOR; GLUTAMIC ACID; JZL 184; LIPOPROTEIN LIPASE; UNCLASSIFIED DRUG; 2-ARACHIDONYLGLYCEROL; ACYLGLYCEROL; ARACHIDONIC ACID DERIVATIVE;

ADULT; AMYGDALOID NUCLEUS; ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BASOLATERAL AMYGDALA; CONTROLLED STUDY; CORPUS STRIATUM; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; GLUTAMATERGIC TRANSMISSION; LIGHT-DARK TEST; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; OPEN FIELD TEST; PREFRONTAL CORTEX; SEX DIFFERENCE; SUCROSE PREFERENCE TEST; TAIL SUSPENSION TEST; ANIMAL; BIOSYNTHESIS; DEPRESSION; DISEASE MODEL; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

AMYGDALA; ANIMALS; ANXIETY; ARACHIDONIC ACIDS; DEPRESSION; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; FEMALE; GLUTAMIC ACID; GLYCERIDES; MALE; MICE, KNOCKOUT; SYNAPTIC TRANSMISSION;

EID: 84915747211     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.11.001     Document Type: Article

References (51)

1. Alger B.E. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog. Neurobiol. 2002, 68:247-286.
2. Azad S.C., Eder M., Marsicano G., Lutz B., Zieglgänsberger W., Rammes G. Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn. Mem. 2003, 10:116-128.
3. Bambico F.R., Cassano T., Dominguez-Lopez S., Katz N., Walker C.D., Piomelli D., Gobbi G. Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus. Neuropsychopharmacology 2010, 35:2083-2100.
4. Buckner J.D., Bonn-Miller M.O., Zvolensky M.J., Schmidt N.B. Marijuana use motives and social anxiety among marijuana-using young adults. Addict. Behav. 2007, 32:2238-2252.
5. Bujarski S.J., Norberg M.M., Copeland J. The association between distress tolerance and cannabis use-related problems: the mediating and moderating roles of coping motives and gender. Addict. Behav. 2012, 37:1181-1184.
6. Busquets-Garcia A., Puighermanal E., Pastor A., de la Torre R., Maldonado R., Ozaita A. Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol. Psychiatry 2011, 70:479-486.
7. Chabrol H., Ducongé E., Casas C., Roura C., Carey K.B. Relations between cannabis use and dependence, motives for cannabis use and anxious, depressive and borderline symptomatology. Addict. Behav. 2005, 30:829-840.
8. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370:1706-1713.
9. Clapper J.R., Mangieri R.A., Piomelli D. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology 2009, 56(Suppl 1):235-243.
10. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA 2002, 99:10819-10824.
11. Domenici M.R., Azad S.C., Marsicano G., Schierloh A., Wotjak C.T., Dodt H.U., Zieglgänsberger W., Lutz B., Rammes G. Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in theforebrain controls glutamatergic synaptic transmission. J.Neurosci. 2006, 26:5794-5799.
12. Etkin A., Wager T.D. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am. J. Psychiatry 2007, 164:1476-1488.
13. Fox C.L., Towe S.L., Stephens R.S., Walker D.D., Roffman R.A. Motives for cannabis use in high-risk adolescent users. Psychology of addictive behaviors 2011, 25:492-500.
14. Gamble-George J.C., Conger J.R., Hartley N.D., Gupta P., Sumislawski J.J., Patel S. Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice. Psychopharmacology (Berl.) 2013, 228:401-409.
15. Gao Y., Vasilyev D.V., Goncalves M.B., Howell F.V., Hobbs C., Reisenberg M., Shen R., Zhang M.Y., Strassle B.W., Lu P., et al. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. The Journal of neuroscience 2010, 30:2017-2024.
16. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., Cassano T., Morgese M.G., Debonnel G., Duranti A., et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. USA 2005, 102:18620-18625.
17. Häring M., Guggenhuber S., Lutz B. Neuronal populations mediating the effects of endocannabinoids on stress and emotionality. Neuroscience 2012, 204:145-158.
18. Hermanson D.J., Hartley N.D., Gamble-George J., Brown N., Shonesy B.C., Kingsley P.J., Colbran R.J., Reese J., Marnett L.J., Patel S. Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nat. Neurosci. 2013, 16:1291-1298.
19. Hill M.N., Gorzalka B.B. Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress. Eur. J. Pharmacol. 2004, 499:291-295.
20. Hill M.N., Patel S. Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biol. Mood Anxiety Disord. 2013, 3:19.
21. Hill M.N., Miller G.E., Ho W.S., Gorzalka B.B., Hillard C.J. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008, 41:48-53.
22. Hill M.N., Patel S., Campolongo P., Tasker J.G., Wotjak C.T., Bains J.S. Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output. J.Neurosci. 2010, 30:14980-14986.
23. Hill M.N., Bierer L.M., Makotkine I., Golier J.A., Galea S., McEwen B.S., Hillard C.J., Yehuda R. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology 2013, 38:2952-2961.
24. Hyman S.M., Sinha R. Stress-related factors in cannabis use and misuse: implications for prevention and treatment. J.Subst. Abuse Treat. 2009, 36:400-413.
25. Jung K.M., Astarita G., Zhu C., Wallace M., Mackie K., Piomelli D. A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Mol. Pharmacol. 2007, 72:612-621.
26. Kano M., Ohno-Shosaku T., Hashimotodani Y., Uchigashima M., Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 2009, 89:309-380.
27. Kathuria S., Gaetani S., Fegley D., Valiño F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 2003, 9:76-81.
28. Levine J., Chengappa K.N., Gershon S., Drevets W. Differentiating primary pathophysiologic from secondary adaptational processes. Depress. Anxiety 2001, 14:105-111.
29. Long J.Z., Li W., Booker L., Burston J.J., Kinsey S.G., Schlosburg J.E., Pavón F.J., Serrano A.M., Selley D.E., Parsons L.H., et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 2009, 5:37-44.
30. Lutz B. Endocannabinoid signals in the control of emotion. Curr. Opin. Pharmacol. 2009, 9:46-52.
31. Moreira F.A., Kaiser N., Monory K., Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 2008, 54:141-150.
32. Moreira F.A., Grieb M., Lutz B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23:133-144.
33. Ohno-Shosaku T., Tanimura A., Hashimotodani Y., Kano M. Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist 2012, 18:119-132.
34. Patel S., Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J.Pharmacol. Exp. Ther. 2006, 318:304-311.
35. Patel S., Hillard C.J. Adaptations in endocannabinoid signaling inresponse to repeated homotypic stress: a novel mechanism for stress habituation. Eur. J. Neurosci. 2008, 27:2821-2829.
36. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 2003, 4:873-884.
37. Ramikie T.S., Nyilas R., Bluett R.J., Gamble-George J.C., Hartley N.D., Mackie K., Watanabe M., Katona I., Patel S. Multiple mechanistically distinct modes of endocannabinoid mobilization at central amygdala glutamatergic synapses. Neuron 2014, 81:1111-1125.
38. Reilly D., Didcott P., Swift W., Hall W. Long-term cannabis use: characteristics of users in an Australian rural area. Addiction 1998, 93:837-846.
39. Rey A.A., Purrio M., Viveros M.P., Lutz B. Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology 2012, 37:2624-2634.
40. Roozendaal B., McEwen B.S., Chattarji S. Stress, memory and the amygdala. Nat. Rev. Neurosci. 2009, 10:423-433.
41. Rossi S., De Chiara V., Musella A., Sacchetti L., Cantarella C., Castelli M., Cavasinni F., Motta C., Studer V., Bernardi G., et al. Preservation of striatal cannabinoid CB1 receptor function correlates with the antianxiety effects of fatty acid amide hydrolase inhibition. Mol. Pharmacol. 2010, 78:260-268.
42. Ruehle S., Rey A.A., Remmers F., Lutz B. The endocannabinoid system in anxiety, fear memory and habituation. J.Psychopharmacol. (Oxford) 2012, 26:23-39.
43. Ruehle S., Remmers F., Romo-Parra H., Massa F., Wickert M., Wortge S., Haring M., Kaiser N., Marsicano G., Pape H.C., Lutz B. Cannabinoid CB1 receptor in dorsal telencephalic glutamatergic neurons: distinctive sufficiency for hippocampus-dependent and amygdala-dependent synaptic and behavioral functions. The Journal of neuroscience 2013, 33:10264-10277.
44. Russo E.B. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neuroendocrinol. Lett. 2008, 29:192-200.
45. Sciolino N.R., Zhou W., Hohmann A.G. Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol. Res. 2011, 64:226-234.
46. Sumislawski J.J., Ramikie T.S., Patel S. Reversible gating of endocannabinoid plasticity in the amygdala by chronic stress: a potential role for monoacylglycerol lipase inhibition in the prevention of stress-induced behavioral adaptation. Neuropsychopharmacology 2011, 36:2750-2761.
47. Tanimura A., Yamazaki M., Hashimotodani Y., Uchigashima M., Kawata S., Abe M., Kita Y., Hashimoto K., Shimizu T., Watanabe M., et al. The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron 2010, 65:320-327.
48. Viveros M.P., Marco E.M., File S.E. Endocannabinoid system and stress and anxiety responses. Pharmacol. Biochem. Behav. 2005, 81:331-342.
49. Yoshida T., Uchigashima M., Yamasaki M., Katona I., Yamazaki M., Sakimura K., Kano M., Yoshioka M., Watanabe M. Unique inhibitory synapse with particularly rich endocannabinoid signaling machinery on pyramidal neurons in basal amygdaloid nucleus. Proc. Natl. Acad. Sci. USA 2011, 108:3059-3064.
50. Yoshino H., Miyamae T., Hansen G., Zambrowicz B., Flynn M., Pedicord D., Blat Y., Westphal R.S., Zaczek R., Lewis D.A., Gonzalez-Burgos G. Postsynaptic diacylglycerol lipase mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal cortex. J.Physiol. 2011, 589:4857-4884.
51. Zhong P., Wang W., Pan B., Liu X., Zhang Z., Long J.Z., Zhang H.T., Cravatt B.F., Liu Q.S. Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling. Neuropsychopharmacology 2014, 39:1763-1776.